---
title: "Why Is Sunshine Biopharma Stock Falling Tuesday?"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286908925.md"
description: "Sunshine Biopharma Inc. (NASDAQ:SBFM) stock fell 18% in premarket trading after announcing a $6 million public offering priced at $0.50 per unit. The offering includes 12 million common units and is expected to close around May 19. The company plans to use the proceeds for general corporate purposes and working capital. SBFM shares were down to $0.41 during premarket trading."
datetime: "2026-05-19T11:28:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286908925.md)
  - [en](https://longbridge.com/en/news/286908925.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286908925.md)
---

# Why Is Sunshine Biopharma Stock Falling Tuesday?

**Sunshine Biopharma Inc.** (NASDAQ:SBFM) stock fell in Tuesday premarket trading, likely pressured by dilution concerns after the company announced the pricing of a $6 million public offering late Monday.

## Public Offering Priced

The pharmaceutical company said the offering includes 12 million common units, or pre-funded units, priced at $0.50 each. Each unit consists of one share of common stock, or one pre-funded warrant, along with two Series C warrants to purchase additional shares at an exercise price of $0.50.

The Series C warrants will be exercisable immediately and will expire five years from the issuance date. The pre-funded warrants will also be immediately exercisable and remain valid until fully exercised.

Sunshine Biopharma said gross proceeds from the offering are expected to total about $6 million before fees and expenses. The transaction is expected to close on or about May 19, subject to customary closing conditions.

The company said it plans to use the net proceeds for general corporate purposes and working capital.

## Drug Pipeline And Generic Portfolio

Sunshine Biopharma currently markets 60 generic prescription drugs in Canada and plans 12 additional launches through the rest of 2026.

The company is also advancing two proprietary drug-development programs, including K1.1 mRNA, an mRNA-lipid nanoparticle therapeutic candidate targeting liver cancer, and a PLpro protease inhibitor program focused on SARS-related coronavirus infections.

## Price Action

**SBFM Price Action:** Sunshine Biopharma shares were down 18.10% at $0.41 during premarket trading on Tuesday, according to Benzinga Pro data.

_Image via Shutterstock_

### Related Stocks

- [SBFM.US](https://longbridge.com/en/quote/SBFM.US.md)
- [SBFMW.US](https://longbridge.com/en/quote/SBFMW.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [SSTK.US](https://longbridge.com/en/quote/SSTK.US.md)

## Related News & Research

- [<![CDATA[Pharmaceutical Executive Daily: FDA Approves Baxdrostat]]>](https://longbridge.com/en/news/286807703.md)
- [NeOnc Advances Glioma Programs and Strengthens Financial Position](https://longbridge.com/en/news/286826865.md)
- [<![CDATA[Regeneron Enters $2.3 Billion Collaboration with Parabilis Medicines to Discover & Develop Multiple Therapeutic Candidates]]>](https://longbridge.com/en/news/286787081.md)
- [BeOne Wins First-in-Class U.S. FDA Nod for BCL2 Drug in Relapsed Mantle Cell Lymphoma](https://longbridge.com/en/news/286330888.md)
- [BridgeBio Pharma Touts Attruby Blockbuster Path, 3 Potential Pipeline Launches](https://longbridge.com/en/news/286199057.md)